Breaking Finance News

Affimed NV (NASDAQ:AFMD) has been downgraded to Hold in a statement by Zacks Investment Research today.

Zacks Investment Research has downgraded Affimed NV (NASDAQ:AFMD) to Hold in a report released on 1/11/2017.

Previously on 02/22/2016, Leerink Swann released a statement about Affimed NV (NASDAQ:AFMD) reduced the target price from $17.00 to $8.00. At the time, this indicated a possible upside of 1.48%.

Only yesterday Affimed NV (NASDAQ:AFMD) traded 2.27% higher at $2.25. The company’s 50-day moving average is $2.04 and its 200-day moving average is $2.49. The last stock close price is down -9.64% from the 200-day moving average, compared to the Standard & Poor's 500 Index which has decreased -0.05% over the same time period. 437,953 shares of AFMD traded hands, up from an average trading volume of 157,121

Recent Performance Chart


Affimed NV has 52 week low of $1.65 and a 52 week high of $5.75 and has a market capitalization of $0.

A total of 5 equity analysts have released a research note on AFMD. Three analysts rating the stock a strong buy, 2 firms rating the stock a buy, one brokerage rating the company a hold, zero brokerages rating the stock a underperform, and finally 0 brokers rating the stock a sell with a average stock price target of $10.52.

More About Affimed NV (NASDAQ:AFMD)

Affimed N.V. is a clinical-stage biopharmaceutical company focused on discovering and developing cancer immunotherapies. The Company's product candidates are developed in the field of immuno-oncology, which represents an approach to cancer research that seeks to harness the body's own immune system to fight tumor cells. Its pipeline includes FM13, AFM11, AFM21, AFM22, AFM24, TandAb and Trispecific Abs. It has started recruitment for Phase IIa clinical trial of AFM13 in patients with Hodgkin Lymphoma. It has initiated a Phase I clinical trial of AFM11 in patients with non-Hodgkin Lymphoma. AFM21 is in preclinical development. AFM22, which is an Epidermal Growth Factor Receptor variant III (EGFRvIII)/CD16A NK-cell TandAb is in preclinical development. AFM24 is an additional CD16A NK-cell TandAb targeting a validated solid tumor target, EGFR-wild type. It is developing Trispecific Abs for treating multiple myeloma, and CD33/CD3-specific T-cell TandAb to treat acute myeloid leukemia.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with's FREE daily email newsletter.